Study summary · research use only
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This mouse study (C57BL/6N recipients, BALB/c donors) examined effects of cibinetide, an innate repair receptor agonist, in an allogeneic intraportal pancreatic islet transplantation model. Streptozotocin-induced diabetic mice received 320 (marginal) or 450 (standard) islets and were treated daily for 14 d with cibinetide (120 µg/kg), with or without tacrolimus (0.4 mg/kg/d) given on days 4-14 after transplantation; graft function, cytokine and proinsulin gene expression, and dendritic cell maturation in vitro were assessed. The authors report that cibinetide was associated with reduced local liver inflammation, improved glycemic control, and delayed onset of allograft loss, with combination treatment alongside low-dose tacrolimus associated with longer-term graft survival; cibinetide was also associated with lowered dendritic cell maturation and reduced allogeneic T-cell response in vitro.
Abstract
During intraportal pancreatic islet transplantation (PITx), early inflammatory reactions cause an immediate loss of more than half of the transplanted graft and potentiate subsequent allograft rejection. Previous findings suggest that cibinetide, a selective innate repair receptor agonist, exerts islet protective and antiinflammatory properties and improved transplant efficacy in syngeneic mouse PITx model. In a stepwise approach toward a clinical application, we have here investigated the short- and long-term effects of cibinetide in an allogeneic mouse PITx model. Streptozotocin-induced diabetic C57BL/6N (H-2) mice were transplanted with 320 (marginal) or 450 (standard) islets from BALB/c (H-2) mice via the portal vein. Recipients were treated perioperative and thereafter daily during 14 d with cibinetide (120 µg/kg), with or without tacrolimus injection (0.4 mg/kg/d) during days 4-14 after transplantation. Graft function was assessed using nonfasting glucose measurements. Relative gene expressions of proinflammatory cytokines and proinsulin of the graft-bearing liver were assessed by quantitative polymerase chain reaction. Cibinetide's effects on dendritic cell maturation were investigated in vitro. Cibinetide ameliorated the local inflammatory responses in the liver and improved glycemic control immediately after allogeneic PITx and significantly delayed the onset of allograft loss. Combination treatment with cibinetide and low-dose tacrolimus significantly improved long-term graft survival following allogeneic PITx. In vitro experiments indicated that cibinetide lowered bone-marrow-derived-immature-dendritic cell maturation and subsequently reduced allogeneic T-cell response. Cibinetide reduced the initial transplantation-related severe inflammation and delayed the subsequent alloreactivity. Cibinetide, in combination with low-dose tacrolimus, could significantly improve long-term graft survival in allogeneic PITx.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.